Appili Austausch ISIN: CA03783R1073 Forum: Aktien User: Nasemütze

👍

Ende 2023 ... das wär ja früh

 2 online    Today  This week    by @businesswire on 13 Jan 2023, 13:19 Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole      Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance of new patent claims for ATI-1501, Appili’s liquid oral reformulation of the antibiotic metronidazole. A notice of allowance is issued by the USPTO to indicate that the application has passed the examination. Metronidazole is a widely used frontline oral treatment with over 10 million prescriptions written in the United States every year to help treat parasitic and anaerobic bacterial infections. The current tablet form of metronidazole is the only approved oral form on the U.S. market, but its bitter taste and lack of appropriate dosage forms for patients with difficulty swallowing often presents treatment compliance challenges. “We are pleased with this notice of allowance for a new patent that will further strengthen ATI-1501’s potential as a more convenient antibiotic treatment option,” said Don Cilla, Pharm.D., M.B.A., President and Chief Executive Officer of Appili Therapeutics. “For far too long, the bitter taste of the current form of metronidazole has made it challenging for patients to take, increasing rates of treatment failure, infection recurrence and antibiotic resistance. This patent protects our investment in making metronidazole more accessible and easier to take for all patients, especially for the elderly and children who often have difficulty taking solid oral medicines.” Appili and their partner Saptalis Pharmaceuticals LLC (“Saptalis”), a New York-based specialty pharmaceuticals company, expect ATI-1501 to be approved by the FDA by the end of 2023.

ja, war echt ein schönes Strohfeuer ...

https://www.businesswire.com/news/home/20221113005149/en/Appili-Therapeutics-ATI-1701-Biodefense-Vaccine-Secures-US14-Million-of-Funding-from-the-U.S.-Department-of-Defense-in-Partnership-with-the-U.S.-Air-Force-Academy

https://globalbiodefense.com/2022/03/03/appili-awarded-10m-in-new-biodefense-funding-for-tularemia-vaccine-candidate/ ... von Anfang des Jahres, etwas Werbung😉

... bei der aktuellen Market cap von ca. 5 mio USD wäre das natürlich ganz nett. Fürs erste wäre ich jedoch froh, wenn sich meine Shares mal von dunkelrot in neutral wandeln würden😂

Auszug: Da es sich bei der kutanen Leishmaniose um eine Tropenkrankheit handelt, wird ATI-1801 nach der Zulassung durch die FDA wahrscheinlich für einen Priority Review Voucher (PRV) in Frage kommen. Ein PRV ermöglicht es dem Inhaber, die Prüfung eines Arzneimittelantrags durch die FDA von den üblichen 10 Monaten auf 6 Monate zu beschleunigen. PRVs sind vollständig übertragbar, und eine Reihe von ihnen wurde in letzter Zeit für jeweils etwa 100 Millionen Dollar verkauft. Neben ATI-1701, einem Impfstoff zur Verhinderung von Infektionen durch den potenziellen Bioterror-Erreger Francisella tularensis, und ATI-2307, dem neuartigen Antimykotikum des Unternehmens, wäre dies das dritte Entwicklungsprodukt von Appili, das für eine PRV in Frage kommt.

https://www.benzinga.com/markets/penny-stocks/22/09/28752593/aplif-advancing-multiple-programs-to-combat-infectious-diseases

Abartig wie die runter geprügelt wurde

https://www.appilitherapeutics.com/pipeline-overview